Femasys Inc. (FEMY) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Femasys Inc.
Address
3950 Johns Creek Court
Suwanee, GA 30024
United States of America (the)
Phone
770 500 3910
Website
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
54
First IPO Date
June 18, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Kathy Lee-Sepsick | Founder, President, Chief Executive Officer & Director | 742,584 | 1968 |
| Dov Elefant | Chief Financial Officer | 594,364 | 1967 |
| James H. Liu | Chief Medical Officer | 0 | N/A |
| Jeffrey Marcus | Chief Medical Advisor | 0 | N/A |
| Benjamin Dings | Vice President of Sales | 0 | N/A |
| Jeremy Alexander Sipos | Chief Technology Officer | 0 | 1974 |
| John Canning | Chief Operating Officer | 0 | 1974 |
| Christine Thomas | Senior Vice President of Regulatory & Clinical Affairs | 0 | 1973 |
| Mary An Merchant | Vice President of Counsel & Intellectual Property | 0 | N/A |
| Megan Eckerman | Senior Vice President of Global Marketing | 0 | N/A |
Description
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
